secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001683168-24-002033
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharma FY2023 net loss $18.9M; Berubicin DSMB OK, enrollment done, topline due H1 2025
--------------------------------------------------------------------------------

- Net loss $18.9M vs $15.3M in 2022; R&D expenses $14.1M (up from $9.3M) on Berubicin trial costs.
- Cash at Dec 31, 2023 only $0.5M; subsequent $4.0M public offering extends runway into late Q2 2024.
- Berubicin GBM study completed enrollment; DSMB recommended continue without modification after interim futility analysis.
- Topline data from potentially pivotal Berubicin trial expected in first half 2025.
- Appointed biotech commercialization leader Amy Mahery to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824002033/0001683168-24-002033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824002033/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-002033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer